Moderna finalizes strategic partnership with UK Government | Daily News Byte


Facilitation to enable access to domestically produced mRNA respiratory vaccines, pending regulatory evaluation and licensure

The ten-year strategic partnership is expected to provide the UK public with response capabilities to ensure future preparedness in light of the Covid-19 pandemic.

Moderna is expanding its presence in the UK through investment in R&D activities and capabilities

Cambridge, MA / AccessWire / December 21, 2022 / Moderna, Inc. (NASDAQ:MRNA), the biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the finalization of a strategic partnership with the UK government to establish a state-of-the-art mRNA research, development and manufacturing facility. The UK follows this landmark agreement in principle between Moderna and the UK Government, announced In June 2022.

“Our new state-of-the-art facility will bring mRNA manufacturing to UK shores, providing the UK public with access to pandemic response capabilities through modern Covid-19 vaccines and future respiratory virus vaccine candidates,” said Chief Executive Officer Stephen Bensall. Moderna. “We look forward to becoming part of the UK’s world-renowned science and innovation community, contributing to the UK health ecosystem through significant investments in R&D activities and expanding our clinical trials footprint across the country.”

Once operational, the Moderna Innovation and Technology Center (MITC) aims to deliver a locally produced portfolio of future mRNA vaccines against respiratory viruses, pending regulatory evaluation and licensing. In addition, the facility aims to provide the UK with direct access to pandemic response capabilities, which will support the UK in its global efforts to mitigate the impact of future pandemics as part of its “100 Day Mission”. As part of the ten-year partnership, Moderna will also support the UK’s mRNA health and science ecosystem.

“We are excited to continue our collaboration with the UK Government and the UK Health Protection Agency to establish the UK as a world-leading mRNA center of excellence,” said Darius Hughes, Moderna’s General Manager for the UK. “When built, our facility will use mRNA science with the goal of developing and manufacturing vaccines that have the potential to address future threats posed by respiratory viruses.”

Construction is expected to begin in early 2023, subject to planning and regulatory approvals, with the facility expected to be operational by 2025.

About Moderna

In its 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA) to an enterprise with a diverse clinical portfolio of vaccines and therapeutics in seven modalities, a broad intellectual property portfolio. in areas including mRNA and lipid nanoparticle formulations, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains connections with a broad range of domestic and foreign government and commercial partners, which has allowed both the pursuit of groundbreaking science and the rapid scaling of production. Recently, Moderna’s capabilities came together to allow the authorized use and approval of one of the earliest and most effective vaccines against the Covid-19 pandemic.

Moderna’s mRNA platform builds on continued advances in basic and applied mRNA science, delivery technology and manufacturing and enables the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past eight years. To know more, visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including: Moderna’s agreement with the UK government to develop an mRNA production facility in the UK, the expected timing of commencement of construction, and when the facility is expected to be operational; types of drugs to be manufactured at the facility; and the company’s support for the UK’s mRNA research, development and industry ecosystem. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna’s control and which Actual results could differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include the other risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and Quarterly Report on Form 10-Q. . The quarterly period ended March 31, 2022, each filed with the US Securities and Exchange Commission (SEC) and subsequent filings with the SEC by Moderna, which are available on the SEC’s website at Except as required by law, Moderna disclaims any intention or obligation to update or revise any forward-looking statements contained in this press release as a result of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.

Moderna Contacts:

International Media: Luke Mircea Willats
Director, Corporate Communications

UK Media: Emma Gilgan-Jones
Director, Communications


Talukdar of Lavina
Senior Vice President and Head of Investor Relations

Source: Moderna, Inc.

See the source version at


Source link